Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eplerenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 known ✓ | P08235 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eplerenone SCHEMBL14567750 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL8445849 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14567731 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14284960 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL16144481 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13061287 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14308852 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13007056 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL21515 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL19891818 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038614-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-07-06 | — | — | EP | disclosed |
| EP-2892519-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015028659-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014037412-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2496226-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | Pharnext (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012117073-A2 | NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011054759-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE | PHARNEXT (FR) | 2011-05-12 | — | — | WO | disclosed |
| US-20070196471-A1 | Micronized Eplerenone Compositions | THOSAR SHILPA S | 2007-08-23 | — | — | US | disclosed |
| EP-1135139-B1 | MICRONIZED EPLERENONE COMPOSITIONS | SEARLE & CO (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6592902-B2 | Aldosterone receptor blockers | THOSAR SHILPA S (US) | 2003-07-15 | — | — | US | disclosed |
| US-6558707-B1 | Micronized particles in carrier such as a purified, micro-crystalline or alkylated cellulose | G. D. SEARLE & CO. | 2003-05-06 | — | — | US | disclosed |
| US-20030072808-A1 | Immediate release eplerenone compositions | THOSAR SHILPA S (US) | 2003-04-17 | — | — | US | disclosed |
| US-6534093-B1 | Immediate release eplerenone compositions | G.D. SEARLE & CO. | 2003-03-18 | — | — | US | disclosed |
| US-6495165-B1 | PARTICLES OF PREGN-4-ENE-7,21-DICARBOXYLIC ACID, 9,11-EPOXY-17-HYDROXY-3-OXO-,GAMMA-LACTONE, METHYL ESTER(7,11,17-ALPHA) AND CARRIERS ADMINISTERED AS ALDOSTERONE RECEPTOR ANTAGONIST FOR PROPHYLAXIS OF CARDIOVASCULAR AND LIVER DISORDERS | G.D. SEARLE & CO. | 2002-12-17 | — | — | US | disclosed |
| US-20020136775-A1 | Controlled release eplerenone compositions | THOSAR SHILPA S (US) | 2002-09-26 | — | — | US | disclosed |
| US-6410054-B1 | Immediate release eplerenone compositions | G. D. SEARLE & CO. | 2002-06-25 | — | — | US | disclosed |
| EP-1135139-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033847-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072808-A1 | Immediate release eplerenone compositions | MC2R, NR3C2, ADRB1 | NR3C2 2/4885NR3C1 19/4885PGR 218/4885 |
| US-20020136775-A1 | Controlled release eplerenone compositions | MC2R, NR3C2, ADRB1 | NR3C2 2/4885NR3C1 24/4885PGR 167/4885 |
| US-20070196471-A1 | Micronized Eplerenone Compositions | NR3C2, MC2R, PTGER1 | NR3C2 1/4885NR3C1 28/4885PGR 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.